Vaccination Program Articles & Analysis: Older
27 news found
(DOI: 10.1038/s41541-022-00534-5) The NIH has renewed funding for the research program as a Phase 2 STTR. The renewed funding will help to move the vaccine closer to human clinical trials. “The use of edible spirulina as a malaria vaccine platform offers a new approach to vaccine development at scales, costs, and delivery ...
Jake Kurtis, identified the parasite protein PfGARP as a target of human antibodies which kill up to 100% of parasites in vitro by inducing apoptosis or parasite programmed cell death – this discovery forms the basis of Ocean Biomedical’s lipid encapsulated mRNA-based vaccine and therapeutic monoclonal antibodies. ...
Approved Quotes “We are proud to work with Ziphius Vaccines in their early-stage program. The advancement of saRNA technologies is an exciting avenue for the development of vaccines and therapeutic programs, and we’re looking forward to a successful partnership.” – Kerstin Dolph, Senior Vice President, ...
The company is pioneering a new class of synthetic, peptide-based immunotherapeutic vaccines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company’s proprietary technology platform has enabled the innovation of novel pipeline ...
ByVaxxinit
(Nasdaq: VAXX), a company pioneering the development of a new class of immunotherapeutic vaccines, today announced that UB-311, an anti-amyloid beta immunotherapeutic vaccine, has been granted Fast Track designation by the U.S. ...
ByVaxxinit
The company is pioneering a new class of synthetic, peptide-based immunotherapeutic vaccines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company’s proprietary technology platform has enabled the innovation of novel pipeline ...
ByVaxxinit
The latter is a more conserved antigen that contains many T cell epitopes and allows for a broad protection against the variants under investigation. The data of this mRNA vaccine candidate are a first promising step towards a broad cross-protective vaccine against SARS-CoV-2” Chris Cardon, CEO of Ziphius Vaccines, said: “Since the ...
(Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced it has completed patient enrollment for Part B of its ongoing Phase 1 clinical trial of UB-312 in Parkinson’s disease (PD). Vaxxinity’s investigational UB-312 vaccine candidate targets pathological forms of alpha-synuclein (aSyn) to ...
ByVaxxinit
VAXIMM technology enables fast generation and delivery of personalized T-cell cancer vaccines and may overcome key issues faced by the neoantigen field NEC OncoImmunity to initiate first clinical trial with lead program from acquisition in 2022 Oslo (Norway)/Tokyo (Japan) and Basel (Switzerland)/Mannheim (Germany) - March 8, 2022: NEC OncoImmunity (NOI), a ...
Oral insulin program continues to advance with topline efficacy data expected in H2 2022 Significant value creation opportunities through oral COVID-19 vaccine program and partnerships Well positioned to capitalize on opportunities with strong cash balance of ~$174 million as of December 3, 2021 Oramed Pharmaceuticals Inc. ...
Vaccitech plc (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced it will host a virtual Key Opinion Leader (“KOL”) event on VTP-300, in development as a key component of a functional cure therapy for chronic hepatitis B (CHB) infection, and the broader ...
Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. “We continue to advance our promising pipeline with the recent publication of data on our MERS vaccine program. We also anticipate that ...
What sets our test apart is that it uses YourBio Health’s innovative blood collection device, that is both convenient and nearly painless.” While COVID-19 vaccines are highly effective, some studies have suggested not all people retain vaccine antibodies for longer than a few weeks or months – potentially leaving them unknowingly at higher ...
INOVIO and CEPI are committed to making a vaccine available as soon as possible for emergency use as a stockpile product post-Phase 2 testing. ...
Based on that theme, we implemented “Sysmex Gives Back Day”, which comprises a program of activities from October through January. While taking preventive measures against the spread of COVID-19, and after considering where we can currently apply our social contribution efforts, we conducted a variety of social contribution activities in various countries and regions, ...
Lilli joins Virometix from Redbiotec AG, where she was CSO, headed the HSV-2 Therapeutic Vaccine Program and built a pipeline based on live biotherapeutics for applications in oncology. ...
And it happened – on December 21, the European Commission approved the conditional approval of the COVID-19 vaccine developed by Pfizer and BioNTech. The decision was based on the opinion of the Committee for Medicinal Products for Human Use at the European Medicines Agency. ...
With the recent approval of a COVID-19 vaccine, there is great hope that there will soon be an end to what is arguably the most painful and deadliest public health crisis in our country’s history. While a mass vaccination program, now underway, will bring healing to a nation that has witnessed more than 300,000 COVID deaths, medical ...
To support accelerated vaccine development in the U.S, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, announced funding to support the expansion of Thermo Fisher's manufacturing capacity for sterile injectables, which can be used to ...
The biopharmaceutical industry is racing to eradicate COVID-19, with nearly 600 programs currently underway to combat the deadly virus, including more than 150 vaccine programs, more than 180 antiviral treatments and more than 250 therapies to treat the various consequences of COVID-19 infection. ...